THTR1 Transporter Assay (SLC19A2)

Thank you for visiting the THTR1 Transporter Assay page. We are working diligently to update this page. In the meantime, please contact us for additional information. THTR1 Transporter Assay Relevance – Vitamin transport Single or Multi-Transporter Model – Single Transporter Type – Uptake Cell Model – MDCK-II Assay Type – Intracellular accumulation Exactly Matched Control Cells – Yes Species – Human Probe Substrate – Thiamine Subcellular Localization in Assay Model – Basolateral Inhibition Positive Control – Amprolium(…)

Optivia Biotechnology Inc and Rhenovia Pharma Sign Partnership Agreement

OPTIVIA BIOTECHNOLOGY AND RHENOVIA PHARMA SIGN A PARTNERSHIP AGREEMENT Companies agree to partner to expand product and service offerings for better understanding drug’s effects in brain. Menlo Park, CA, Mulhouse, France, Cambridge, MA (PRWEB) May 20, 2015 – Optivia Biotechnology, the leading provider of high quality transporter assay services for Drug-Drug Interactions (DDI), Metabolism and(…)

Vitamin Transporters. How Critical Are They?

It is a fact that humans have lost the ability to synthesize most water soluble vitamins.  We therefore rely on exogenous sources to provide these precious substances that are essential for normal human health and wellbeing [1].  Absorbing these vitamins and bringing them to their sites of action, both systemic and local, involve complicated cellular(…)

Optivia Publishes Paper with Incyte Corporation

Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110. Zhang Y, et al. Drug Metab Dispos. 2015. Authors Zhang Y1, Warren MS2, Zhang X2, Diamond S2, Williams B2, Punwani N2, Huang J2, Huang Y2, Yeleswaram S2. Author information 1Incyte Corporation, Wilmington, Delaware (Y.Z., S.D., B.W., N.P., S.Y.), and Optivia Biotechnology, Menlo Park, California (M.W., X.Z.,(…)

Leslie Benet, Ph.D., Chairman of Scientific Advisory Board

Leslie Benet, Ph.D., Chairman of Scientific Advisory Board Dr. Benet is a professor and former Chairman (1978-1998) of the Department of Biopharmaceutical Sciences, UC San Francisco. His research interests, more than 480 publications, 7 books and 11 patents are in the areas of pharmacokinetics, biopharmaceutics and the role of transporters in PK/PD. Dr. Benet is(…)

Optivia Forms Technology & Marketing Alliance with Hurel

OPTIVIA BIOTECHNOLOGY FORMS TECHNOLOGY & MARKETING ALLIANCE WITH HUREL CORPORATION Firms partner to improve understanding of in vitro/in vivo correlation for transporter-mediated hepatic clearance, drug-drug interactions, and drug-induced liver injury

Optivia Appoints Dr. Jean-Michel Scherrmann to SAB

OPTIVIA BIOTECHNOLOGY APPOINTS DR. JEAN-MICHEL SCHERRMANN TO SCIENTIFIC ADVISORY BOARD Preeminent Neuropsychopharmacology and Neuropharmacokinetics Scientist Joins Scientific Advisory Board Menlo Park, CA — 02/11/2015 – Optivia Biotechnology Inc. announced today the appointment of Dr. Jean‑Michel Scherrmann to the Company’s Scientific Advisory Board (SAB). Dr. Scherrmann is a preeminent scientist with expertise in drug transporters in neuropharmacokinetics(…)

Jean-Michel Scherrmann, Ph.D., Scientific Advisor

Jean-Michel Scherrmann, Pharm. D., Ph. D. is Professor in the Department of Pharmacokinetics, Faculty of Pharmacy, the University Paris Descartes. He received his Pharm.D. and Ph. D. in analytical radiochemistry from the University Descartes at Paris. He has led the Neuropsychopharmacology Unit at the French Institute of Health and Medical Research (INSERM) and the National(…)